Sofosbuvir

Paul A. Pham, Pharm.D., David L. Thomas, M.D., M.P.H., Janessa M. Smith, Pharm.D. BCPS
Sofosbuvir is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Treatment of HCV genotype 1, 2, 3 or 4 as a component of a combination antiviral treatment regimen
  • Indicated in patients with hepatocellular carcinoma, those awaiting liver transplantation, and those with HCV/HIV-1 co-infection

NON-FDA APPROVED USES

  • In combination with an HCV active antiviral regimen, sofosbuvir’s (SOF) efficacy has been established in patients with HCV genotype 5 and 6

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

  • Treatment of HCV genotype 1, 2, 3 or 4 as a component of a combination antiviral treatment regimen
  • Indicated in patients with hepatocellular carcinoma, those awaiting liver transplantation, and those with HCV/HIV-1 co-infection

NON-FDA APPROVED USES

  • In combination with an HCV active antiviral regimen, sofosbuvir’s (SOF) efficacy has been established in patients with HCV genotype 5 and 6

There's more to see -- the rest of this entry is available only to subscribers.

Last updated: April 6, 2017